PATENT CLAIM ANALYSIS

Application Number: 16152088
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["544", "236000"]

Abstract:
The invention is directed to a triazolopyridazine compound of formula (I): N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Claim (Index 2):
A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) a N-oxide, a pharmaceutically acceptable salt or solvate thereof, wherein D represents deuterium, and wherein the deuterium content in the 2-position of the quinoline at the D position is at least 50%.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.98462
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15531780', '11377077', '12187524', '15128342', '15300284']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7527098364705928
- 35 USC 102 Novelty (BERT): 0.4945937045020575
- Combined Prediction Score: 0.7268982232737392
- Mean Citation Score: 207.14297
- Max Citation Score: 278.1651
- Similarity Product: 234.79775119133592

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test